Mother Jones Magazine [Unofficial]The Mighty Colorado Is Vanishing, and the Fixes Are Getting Weird
AbangeLabsSweden restricted Evfraxy reimbursement after treating EMA biosimilar comparability and cost parity as central access evidence. https://www.mattheneus.com/editorial/tlv-evfraxy-denosumab-osteoporosis-limited-reimbursement-prolia-biosimilar-2026-04-28 #HTA #Pharma #RegulatoryAffairs
Sweden limits Evfraxy reimbursement to osteoporosis and prostate-cancer bone-loss populations
Sweden decided that Evfraxy, a denosumab biosimilar referencing Prolia, should enter the high-cost protection scheme with a restricted reimbursement scope. The Dental and Pharmaceutical Benefits Agency (TLV) relied on European Medicines Agency biosimilar comparability and a cost comparison showing the same cost as the most cost-effective relevant alternative.
Sweden's TLV rejected a syringe reimbursement price increase because access-risk claims lacked quantified benefits-use evidence. https://www.mattheneus.com/editorial/tlv-fixed-needle-syringe-price-increase-rejection-low-benefits-use-2026-06-16 #HTA #EvidenceSynthesis #RegulatoryAffairs
Swedish Dental and Pharmaceutical Benefits Agency rejects fixed-needle syringe price increase
The Swedish Dental and Pharmaceutical Benefits Agency rejected Becton Dickinson Sweden ABs request for higher reimbursement prices for two fixed-needle 1 ml syringes. The decision turned on benefits-use data, not clinical efficacy, and shows how access-risk claims need quantified reimbursement evidence.
TLV's Fluttasino rejection shows how an economic model gap can outweigh clinical rationale in reimbursement review. https://www.mattheneus.com/editorial/tlv-fluttasino-nasal-polyps-non-reimbursement-economic-model-gap-2026-04-23 #HTA #HealthEconomics #RegulatoryAffairs
Sweden's Dental and Pharmaceutical Benefits Agency (TLV) rejects Fluttasino reimbursement after model gap
Sweden's Dental and Pharmaceutical Benefits Agency (TLV) rejected Fluttasino reimbursement for chronic rhinosinusitis with nasal polyps after concluding that the submitted economic model did not reflect the expected treatment pathway.
Sweden's Gotenfia decision is a useful reminder that biosimilar reimbursement can hinge on comparator framing as much as headline price. https://www.mattheneus.com/editorial/tlv-gotenfia-golimumab-biosimilar-limited-reimbursement-simponi-gobivaz-cost-comparison-2026-04-28 #HTA #Pharma #RegulatoryAffairs
Sweden reimburses Gotenfia with a biosimilar comparator restriction
Sweden's Dental and Pharmaceutical Benefits Agency will reimburse Gotenfia from 28 April 2026 with a restriction tied to etanercept or adalimumab suitability. The agency accepted comparable effect and safety versus Simponi and Gobivaz, then based the decision on medicine-cost comparison.
A small consumable pricing case shows how Swedish HTA scrutiny can turn on evidence for cost justification, even for routine devices. https://www.mattheneus.com/editorial/tlv-microlance-consumable-cost-evidence-2026-06-23 #HTA #HealthEconomics #RegulatoryAffairs
Swedish reimbursement agency refuses Microlance 3 injection needle price increase
On 22 June 2026, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) refused a price increase for Microlance 3 injection needles. For health technology assessment (HTA) and market-access teams, the decision separates patient-need evidence from economic evidence showing that a product is likely to leave reimbursement without a higher price.
A July 2026 TLV withdrawal list shows how package-level reimbursement status can become the immediate market-access risk, even without new clinical evidence. https://www.mattheneus.com/editorial/tlv-july-2026-medicine-withdrawals-reimbursement-continuity-ledger-2026-06-09 #HTA #RegulatoryAffairs #HealthEconomics
Swedish Dental and Pharmaceutical Benefits Agency lists July 2026 medicine withdrawals from reimbursement
The Swedish Dental and Pharmaceutical Benefits Agency published medicines leaving the pharmaceutical benefits scheme from 1 July 2026 at company request, including Votrient packages and Waran tablets.
Sweden keeps codeine access stable during a licensed-medicine transition, a useful reminder that reimbursement continuity can be the real access question. https://www.mattheneus.com/editorial/tlv-kodein-extractumpharma-temporary-reimbursement-licensed-medicine-transition-2026-05-13 #HTA #RegulatoryAffairs #Pharma
Swedish reimbursement agency grants temporary subsidy for Kodein ExtractumPharma during licensed-medicine transition
Tandvårds- och läkemedelsförmånsverket (TLV) granted temporary reimbursement for Kodein ExtractumPharma from 13 May 2026 for patients already treated with the product or a replaceable licensed codeine medicine, while the ordinary reimbursement application remains under review.
Sweden accepted a Levaxin price increase to protect supply continuity, showing how HTA and reimbursement decisions can reflect access risk. https://www.mattheneus.com/editorial/tlv-levaxin-price-increase-supply-continuity-hypothyroidism-2026-06-15 #HTA #RegulatoryAffairs #Pharma
Unit-cost comparator reviews can sink even familiar device submissions. TLV's Menalancets decision is a reminder to document price, comparator, and claimed benefit as one evidence story. https://www.mattheneus.com/editorial/tlv-menalancets-lancets-rejection-vitrex-unit-cost-comparator-2026-05-13 #HTA #HealthEconomics #RegulatoryAffairs
Sweden's Dental and Pharmaceutical Benefits Agency rejects Menalancets after unit-cost comparator review
Sweden's Dental and Pharmaceutical Benefits Agency rejected Menalancets for reimbursement after selecting Vitrex Soft Lancetter 28G as the relevant comparator and finding the requested price higher on a per-lancet basis.